Results 31 to 40 of about 15,940 (198)
Oncolytic Virotherapy: From Bench to Bedside
Frontiers in Cell and Developmental Biology, 2021 Oncolytic viruses are naturally occurring or genetically engineered viruses that can replicate preferentially in tumor cells and inhibit tumor growth. These viruses have been considered an effective anticancer strategy in recent years.
Ludi Yang +9 more
doaj +1 more source
Oncolytic viruses and cancer treatment
Klinicka onkologie, 2023 The fundamental difference between tumor and normal tissue growth is the emergence of the microenvironment with diminished or extinguished immunogenicity. One of the main functions of oncolytic viruses is the formation of such a microenvironment, which leads to a revival of immunological processes and loss of viability of cancer cells.
H, Španielová, R, Brdička
openaire +2 more sources
Oncolytic viruses: overcoming translational challenges [PDF]
Journal of Clinical Investigation, 2019 Oncolytic virotherapy (OVT) is a promising approach in which WT or engineered viruses selectively replicate and destroy tumor cells while sparing normal ones. In the last two decades, different oncolytic viruses (OVs) have been modified and tested in a number of preclinical studies, some of which have led to clinical trials in cancer patients.
Jordi Martinez-Quintanilla +3 more
openaire +2 more sources
Journal of Translational Medicine, 2012 Oncolytic viruses refer to those that are able to eliminate malignancies by direct targeting and lysis of cancer cells, leaving non-cancerous tissues unharmed.
Patil Sandeep S +4 more
doaj +1 more source
Evolving role of seneca valley virus and its biomarker TEM8/ANTXR1 in cancer therapeutics
Frontiers in Molecular Biosciences, 2022 Oncolytic viruses have made a significant inroad in cancer drug development. Numerous clinical trials are currently investigating oncolytic viruses both as single agents or in combination with various immunomodulators.
Virginia Corbett +3 more
doaj +1 more source
Pre‐Encoded IFN‐I Sensitivity Exacerbates Memory T Cell Senescence in Solid Tumors
Advanced Science, EarlyView.Type I interferon (IFN‐I) signaling promotes p21‐dependent cell cycle arrest in senescent tumor‐specific memory T cells, resulting in poor proliferative responses and solid tumor regression during cancer vaccination. Conversely, IFNα/β receptor blockade reinvigorates T cell proliferation to regress solid tumors and is more effective with increasing ...
Andrew Nguyen +4 more
wiley +1 more source
Advances in preclinical and clinical studies of oncolytic virus combination therapy
Frontiers in OncologyOncolytic viruses represent a distinct class of viruses that selectively infect and destroy tumor cells while sparing normal cells. Despite their potential, oncolytic viruses encounter several challenges as standalone therapies.
Wenlong Du +4 more
doaj +1 more source
Logic‐Gated HSV‐TK/GCV Suicide Gene Circuit for Triple‐Negative Breast Cancer
Advanced Science, EarlyView.The BRAS comprises two modular genetic components driven by distinct tumor‐specific promoters and a failsafe layer with the NOT gate. This multi‐input logic gate circuit enables precise, specific expression of HSV‐TK in breast cancer cells with hardly expression in normal cell and effectively inhibits tumor growth in a triple‐negative breast cancer ...
Shasha Tang +10 more
wiley +1 more source
MedComm – Oncology, 2023 The most deadly and aggressive form of brain cancer is called a glioblastoma multiforme. Following diagnosis, the median duration of survival is only 14 months.
Tanvir Ahmed
doaj +1 more source
GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy
Advanced Science, EarlyView.Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu +11 more
wiley +1 more source